Neutrophil Elastase (NE) is a protease secreted by neutrophils. Neutrophils are the first responders of the innate immune system and play a crucial role in fighting invading pathogens. Thought to be indiscriminate killers, research shows neutrophils are implicated in chronic inflammatory diseases and contribute to injury repair.
Better understand neutrophilic response in vivo with IVISense™ Neutrophil Elastase 680 FAST NIR fluorescent probe. IVISense Neutrophil Elastase 680 probe can detect NE post-degranulation or netosis from activated neutrophils.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
IVISense Neutrophil Elastase 680 FAST™ is a member of a family of activatable fluorescent imaging agents comprising a novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology) that confers an improved pharmacokinetic profile with a broader range of early imaging time points. This architecture also offers higher target specific signal with reduced background.
This NIR agent is a neutrophil elastase activatable agent that is optically silent upon injection and produces fluorescent signal after cleavage by elastase produced by neutrophil cells. Neutrophil elastase is a key protease involved in acute lung injury, acute respiratory distress syndrome, as well as many other inflammatory processes such as emphysema, cystic fibrosis, COPD, wound healing, rheumatoid arthritis, ischemia-reperfusion and many others.
IVISense Neutrophil Elastase 680 FAST fluorescent imaging agent is a selective neutrophil elastase-activatable agent designed for imaging of this serine protease both in vitro and in vivo. The half-life in plasma of Neutrophil Elastase 680 FAST is 4 hours.
|Fluorescent Agent Type||Activatable|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.
A novel NIR dye for in vivo temporal tracking of labeled macrophages to sites of acute inflammation
We have demonstrated the ability of our Fluorescence Tomography (FMT 2500) in vivo imaging system and ProSense 680 to non-invasively visualize and quantify inflammation in the lung in a robust and validated manner. The consistency of the quantitative tomography, as well as its excellent correlation with BAL assessment of eosinophilia, provide a powerful toolkit for quantifying the therapeutic efficacy of dexamethasone treatment. Utilizing new and existing imaging agents, FMT imaging in asthma research provides useful, non-invasive tools for understanding pulmonary inflammation and for developing new therapeutics in vivo.
Neutrophil Elastase 680 FAST activatable fluorescent imaging agent Protocol
Neutrophil Elastase 680 FAST™ is a member of a family of activatable fluorescent imaging agents comprising a novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology) that confers an improved pharmacokinetic profile with a broader range of early imaging time points. This architecture also offers higher target specific signal with reduced background.
Long known as the immune system's first line of defense against bacterial invaders, neutrophils have sparked renewed interest as their proinflammatory response is implicated in the progression and severity of viral diseases, including SARS-CoV-2. As more is learned about their role in respiratory viral infections and subsequent complications, the factors that determine clinical progression into conditions such as acute respiratory distress syndrome (ARDS) may be better understood.
Learn how in vivo imaging using Neutrophil Elastase 680, a NIR fluorescent probe to detect activated neutrophils in affected tissue such at lung, can help reveal the biology of neutrophilic response in the context of pathologic lung injury, advancing what we know of viral respiratory infections.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.